CIRc-014 is an orally active Cyclin A/B inhibitor with a Cyclin A IC50 of 0.05 µM, Cyclin A Kd of 2.7 nM, Cyclin B IC50 of less than 0.02 µM and Cyclin B Kd of 1.0 nM. CIRc-014 activates the spindle assembly checkpoint and promotes the formation of a complex between Cyclin B and CDK2 by blocking the RxL interaction of Cyclin A/B. CIRc-014 can induce replication stress, DNA damage, mitotic arrest and apoptosis in tumor cells. CIRc-014 showed tumor growth inhibition and regression in NCI-H69 and NCI-H446 small cell lung cancer xenograft models. CIRc-014 can be used for the research of small-cell lung cancer[1][2].
Molekulargewicht:
962.46
CAS Nummer:
[3064485-73-7]
Formel:
C45H62ClF6N7O7
Target-Kategorie:
Apoptosis,CDK
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
